Table 7.
Patient outcomes by induction agent used in patients with ISS > 16 (n = 664)
| Induction agent | IRR (95% CI) | p-value | Predicted LOS/complication rate (95% CI) |
|---|---|---|---|
| ICU LOS | |||
| Propofol | Ref | Ref | 18.8 (11.7–25.8) |
| Ketamine | 0.8 (0.6–1.2) | 0.27 | 15.1 (11.4–18.9) |
| Etomidate | 0.7 (0.4–1.0) | 0.041 | 12.2 (11.1–13.4) |
| Total hospital LOS | |||
| Propofol | Ref | Ref | 36.0 (22.0–49.9) |
| Ketamine | 0.7 (0.5–1.1) | 0.11 | 26.2 (19.6–32.8) |
| Etomidate | 0.5 (0.3–0.8) | 0.003 | 18.8 (16.–20.7) |
| Days on MV | |||
| Propofol | Ref | Ref | 10.5 (6.0–15.0) |
| Ketamine | 1.0 (0.6–1.5) | 0.96 | 10.4 (7.6–13.1) |
| Etomidate | 0.9 (0.5–1.4) | 0.50 | 9.0 (8.1–9.8) |
| Number of complications | |||
| Propofol | Ref | Ref | 1.2 (0.7–1.8) |
| Ketamine | 1.4 (0.9–2.3) | 0.14 | 1.7 (1.2–2.2) |
| Etomidate | 2.1 (1.2–3.4) | 0.005 | 2.5 (2.2–2.9) |
By negative binomial regression. All models are adjusted for hospital site, age, revised trauma score (RTS), traumatic brain injury (TBI), and induction location. The NB model for complications was offset by the total length of stay (LOS)
ICU intensive care unit, LOS length of stay, MV mechanical ventilation